Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Presentation TCT 2024

TCT 242: Prospective Validation of the ARC-HBR, PRECISE-DAPT, and PARIS Risk Prediction Model in the All-Comer PIONEER IV Trial

Presenter: TsungYing Tsai

October 28, 2024

Presentation TCT 2024

From ARC-HBR and PRECISE-DAPT to PRECISE-2: Development and Validation of a Novel Universal Bleeding Risk Score

Presenter: Marco Valgimigli

October 27, 2024

News Conference News SCAI 2021

Chinese Registry Supports Prolonged DAPT Following PCI for ACS

Yael L. Maxwell

May 03, 2021

News Industry News

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

October 17, 2020

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

News Daily News

June 2020 News Roundup

L.A. McKeown

June 01, 2020

News Industry News

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

June 01, 2020

News Daily News

Validated ARC-HBR Criteria Highlight ‘Eye-opening’ Proportion of PCI Patients at Risk

Yael L. Maxwell

March 03, 2020

Presentation TCT 2019

Idenifying the High Bleeding Risk Patient: The ARC HBR Definitions

Presenter: Philip Urban

September 27, 2019

News Conference News EuroPCR 2019

New Clarity on Patients at High Risk for Bleeding After PCI

Michael O'Riordan

May 28, 2019

Advertisement

TCT 242: Prospective Validation of the ARC-HBR, PRECISE-DAPT, and PARIS Risk Prediction Model in the All-Comer PIONEER IV Trial

From ARC-HBR and PRECISE-DAPT to PRECISE-2: Development and Validation of a Novel Universal Bleeding Risk Score

Chinese Registry Supports Prolonged DAPT Following PCI for ACS

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

June 2020 News Roundup

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

Validated ARC-HBR Criteria Highlight ‘Eye-opening’ Proportion of PCI Patients at Risk

Idenifying the High Bleeding Risk Patient: The ARC HBR Definitions

New Clarity on Patients at High Risk for Bleeding After PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content